文献速递真菌感染新发突发、热带与寄生虫病医院感染防控

早期抗真菌预防未能预防ICU流感相关肺曲霉病:一项目标试验模拟

Early antifungal prophylaxis fails to prevent influenza-associated pulmonary aspergillosis in the ICU: a target trial emulation.
PubMed 文献 · Clin Microbiol Infect · 2026-05-29

该研究采用多中心队列(48个ICU,2023-2025年)模拟目标试验,评估早期抗真菌预防对重症流感成人流感相关肺曲霉病(IAPA)的影响。在2919例患者中,经逆概率加权调整后,预防组与非预防组IAPA风险无显著差异(HR 0.88,95%CI 0.48-1.63;p 0.693),且预防与肝毒性风险增加相关(调整OR 1.58,95%CI 1.35-1.86;p<0.001)。结论提示不推荐普遍预防策略。

要点

  • 早期抗真菌预防未显著降低ICU流感患者IAPA总体发生率。
  • 预防与肝毒性风险增加相关,未改善临床结局。
  • 仅在高基线IAPA发生率ICU亚组中观察到保护性关联。

核心结论

  • 早期抗真菌预防未降低IAPA总体发生率,且与肝毒性增加相关,未改善临床结局。

研究设计与样本

  • 多中心队列研究,纳入48个ICU的2919例重症流感成人,采用目标试验模拟和逆概率加权控制混杂。

主要发现

  • 粗分析中预防组IAPA发生率3.6%(16/448),非预防组7.6%(189/2471),HR 0.46(95%CI 0.27-0.76)。
  • 加权调整后预防无显著保护效应(HR 0.88,95%CI 0.48-1.63;p 0.693)。
  • 预防与肝毒性风险增加相关(调整OR 1.58,95%CI 1.35-1.86;p<0.001),对肾毒性、ICU转出和死亡率无显著影响。
  • ICU基线IAPA发生率存在显著效应修饰(交互p<0.001),仅最高发生率三分位组观察到保护关联(HR 0.28,95%CI 0.08-0.91)。

临床怎么用

  • 不支持对ICU重症流感患者普遍实施早期抗真菌预防。
  • 可考虑在高基线IAPA发生率的ICU中个体化评估预防策略。
  • 预防决策需权衡肝毒性风险。

局限性

  • 观察性设计可能残余混杂,尽管采用了目标试验模拟和逆概率加权。
  • 预防策略的异质性提示结果可能受ICU特异性因素影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate whether early antifungal prophylaxis reduces the incidence of influenza-associated pulmonary aspergillosis (IAPA) in critically ill adults with influenza. METHODS: We emulated a target trial using a multicentre cohort of critically ill adults with influenza from 48 intensive care units (ICUs) (2023-2025). The intervention was antifungal prophylaxis within 24 hours of ICU admission versus no prophylaxis. We used directed acyclic graphs and inverse probability of treatment weighting to control for confounding. The primary outcome was IAPA incidence after the first 48 hours of ICU stay. Secondary outcomes included hepatotoxicity, nephrotoxicity, 14-day nondeath ICU discharge, and 28-day all-cause mortality. RESULTS: Among 2919 eligible patients, 448 (15.3%) received early prophylaxis. The overall incidence of IAPA was 7.0%. In the crude analysis, IAPA occurred in 16 of 448 (3.6%) patients in the prophylaxis group versus 189 of 2471 (7.6%) in the no prophylaxis group, corresponding to a reduced hazard (hazard ratio [HR] 0.46, 95% CI 0.27-0.76). However, after inverse probability of treatment weighting adjustment to emulate randomization, prophylaxis showed no significant protective effect (HR 0.88, 95% CI 0.48-1.63; p 0.693). Subgroup analysis revealed significant effect modification by ICU-specific baseline IAPA incidence (p for interaction <0.001), with a protective association observed only in the highest incidence tertile (HR 0.28, 95% CI 0.08-0.91). Prophylaxis was associated with an increased risk of hepatotoxicity (adjusted OR 1.58, 95% CI 1.35-1.86; p < 0.001) but showed no significant effect on nephrotoxicity, ICU discharge, or mortality. CONCLUSIONS: Early antifungal prophylaxis did not reduce IAPA incidence overall and was associated with increased hepatotoxicity, without improving clinical outcomes. The observed heterogeneity across ICUs suggests that a universal prophylaxis strategy is not justified.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Li P, Xu S, Chen C, et al. Early antifungal prophylaxis fails to prevent influenza-associated pulmonary aspergillosis in the ICU: a target trial emulation. Clin Microbiol Infect. 2026. PMID: 42114720. doi:10.1016/j.cmi.2026.05.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。